Aliases & Classifications for Vaccinia

MalaCards integrated aliases for Vaccinia:

Name: Vaccinia 12 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3298
MeSH 45 D014615
UMLS 74 C0042214

Summaries for Vaccinia

Disease Ontology : 12 A viral infectious disease that results in infection, located in skin, has material basis in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted by contact with the vaccination site before it has healed, or transmitted by fomites that have been contaminated with live virus from the vaccination site. The infection has symptom rash, has symptom fever, and has symptom body aches.

MalaCards based summary : Vaccinia is related to cowpox and smallpox, and has symptoms including fever, rash and body aches. An important gene associated with Vaccinia is VRK1 (VRK Serine/Threonine Kinase 1), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and skin, and related phenotypes are hematopoietic system and immune system

Wikipedia : 77 Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It... more...

Related Diseases for Vaccinia

Diseases related to Vaccinia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 cowpox 11.5
2 smallpox 10.8
3 variola major 10.6
4 influenza 10.5
5 hepatitis 10.4
6 melanoma 10.4
7 encephalitis 10.4
8 chromosome 2p16.1-p15 deletion syndrome 10.4 BANF1 VRK2
9 monkeypox 10.4
10 human immunodeficiency virus type 1 10.3
11 rabies 10.3
12 malaria 10.3
13 hepatitis c 10.3
14 stomatitis 10.2
15 hepatitis c virus 10.2
16 dermatitis 10.2
17 herpes simplex 10.2
18 breast cancer 10.2
19 japanese encephalitis 10.2
20 measles 10.2
21 severe acute respiratory syndrome 10.2
22 prostate cancer 10.1
23 pancreatic cancer 10.1
24 prostate cancer, hereditary, 8 10.1
25 prostate cancer, hereditary, 6 10.1
26 hepatitis b 10.1
27 glioma 10.1
28 murray valley encephalitis 10.1 ERVW-1 IL2
29 eczema herpeticum 10.1 IRF3 IRF7
30 colorectal cancer 10.1
31 hepatocellular carcinoma 10.1
32 dermatitis, atopic 10.1
33 adenocarcinoma 10.1
34 leukemia 10.1
35 leishmaniasis 10.1
36 yellow fever 10.1
37 t-cell adult acute lymphocytic leukemia 10.1 ERVW-1 IL2
38 fibroma 10.1
39 molluscum contagiosum 10.1
40 mumps 10.0
41 sarcoma 10.0
42 lymphocytic choriomeningitis 10.0
43 papilloma 10.0
44 newcastle disease 10.0
45 venezuelan equine encephalitis 10.0
46 alzheimer disease 10.0
47 myeloma, multiple 10.0
48 cervical cancer 10.0
49 noonan syndrome 3 10.0
50 cutaneous leishmaniasis 10.0

Graphical network of the top 20 diseases related to Vaccinia:



Diseases related to Vaccinia

Symptoms & Phenotypes for Vaccinia

Symptoms:

12
  • fever
  • rash
  • body aches

MGI Mouse Phenotypes related to Vaccinia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 AZI2 BTRC DUSP3 EIF2AK2 EPS15 IL2
2 immune system MP:0005387 9.32 AZI2 BTRC EIF2AK2 EPS15 IL2 IRF3

Drugs & Therapeutics for Vaccinia

Drugs for Vaccinia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
2 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Phase 1
4 gamma-Globulins Phase 4,Phase 3,Phase 2,Phase 1
5 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
6 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
7 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Phase 1
8
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
9
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 33069-62-4 36314
10
Carboplatin Approved Phase 2, Phase 3,Not Applicable 41575-94-4 38904 10339178 498142
11
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
12
Cisplatin Approved Phase 2, Phase 3,Phase 1 15663-27-1 441203 84093 2767
13
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
14
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
15
Pemetrexed Approved, Investigational Phase 2, Phase 3 150399-23-8, 137281-23-3 60843 446556
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
17 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
19 Analgesics Phase 3,Phase 2,Phase 1
20 Anticonvulsants Phase 3
21 Neurotropin Phase 3
22 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
23 Iron-Dextran Complex Phase 3,Phase 2
24 polysaccharide-K Phase 3,Phase 2,Phase 1
25 Protein Kinase Inhibitors Phase 3,Phase 2
26 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
27 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 1,Not Applicable
28 Antimitotic Agents Phase 2, Phase 3,Phase 1
29 Antiviral Agents Phase 2, Phase 3,Phase 1
30 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
31 Antimetabolites Phase 2, Phase 3,Phase 1
32 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
33 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 1
34 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
35 Folate Phase 2, Phase 3
36 Vitamin B9 Phase 2, Phase 3
37 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
38 Antineoplastic Agents, Phytogenic Phase 2, Phase 3
39 Folic Acid Antagonists Phase 2, Phase 3
40 Vitamin B Complex Phase 2, Phase 3
41
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
42
Sargramostim Approved, Investigational Phase 1, Phase 2,Phase 2 123774-72-1, 83869-56-1
43
Metronidazole Approved Phase 2,Phase 1,Not Applicable 443-48-1 4173
44
Goserelin Approved Phase 2 65807-02-5 5311128 47725
45
Bicalutamide Approved Phase 2 90357-06-5 2375 56069
46
Oxaliplatin Approved, Investigational Phase 1, Phase 2 61825-94-3 6857599 5310940 9887054 43805
47
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
48
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
49
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
50
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4

Interventional clinical trials:

(show top 50) (show all 260)
# Name Status NCT ID Phase Drugs
1 Special Access Program IMVAMUNE® Completed NCT03472014 Phase 4
2 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
3 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Recruiting NCT02443623 Phase 4
4 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT01144637 Phase 3
5 VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV Completed NCT01158157 Phase 3
6 Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
7 Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
8 Analgecine for the Treatment of Neuropathic Pain Completed NCT02633618 Phase 3
9 A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543567 Phase 3
10 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543268 Phase 3
11 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Recruiting NCT02562755 Phase 3 Sorafenib
12 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
13 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
14 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Active, not recruiting NCT01913353 Phase 3
15 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Active, not recruiting NCT02509494 Phase 3
16 Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial Not yet recruiting NCT03699124 Phase 3
17 Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Terminated NCT01383148 Phase 2, Phase 3 placebo
18 Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002817 Phase 1, Phase 2
19 Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Unknown status NCT00103584 Phase 1, Phase 2
20 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
21 A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis Completed NCT01443260 Phase 1, Phase 2
22 Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma Completed NCT00116597 Phase 1, Phase 2
23 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT00554372 Phase 2
24 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
25 Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) Completed NCT01705223 Phase 2
26 A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma Completed NCT00429312 Phase 1, Phase 2
27 High Dose IMVAMUNE® in Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
28 PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer Completed NCT00088413 Phase 2 Sargramostim (GM-CSF, Leukine)
29 A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
30 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Completed NCT00108732 Phase 2 Bicalutamide;Goserelin Acetate
31 Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma Completed NCT01394939 Phase 1, Phase 2 Irinotecan
32 APSV in Vaccinia Naive Adults Completed NCT00050518 Phase 2
33 A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib Completed NCT01387555 Phase 2
34 Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Completed NCT00038987 Phase 1, Phase 2
35 A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer Completed NCT01636284 Phase 2
36 A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT01171651 Phase 2 JX-594 followed by sorafenib
37 Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer Completed NCT00179309 Phase 2 Docetaxel
38 Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally Completed NCT00914732 Phase 2
39 Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Completed NCT02919306 Phase 1, Phase 2 Placebo
40 ACAM 3000 MVA at Harvard Medical School Completed NCT00133575 Phase 1, Phase 2
41 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00019734 Phase 2
42 Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00054535 Phase 2
43 Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Completed NCT00112957 Phase 2
44 Dressing Preparations for Smallpox Completed NCT00063856 Phase 1, Phase 2
45 A Study of MVA85A in Healthy Children and Infants Completed NCT00679159 Phase 2
46 Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors Completed NCT00003125 Phase 2
47 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
48 Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults Completed NCT00820846 Phase 2
49 MVA Post-Event: Administration Timing and Boost Study Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
50 Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines Completed NCT01461447 Phase 1, Phase 2

Search NIH Clinical Center for Vaccinia

Cochrane evidence based reviews: vaccinia

Genetic Tests for Vaccinia

Anatomical Context for Vaccinia

The Foundational Model of Anatomy Ontology organs/tissues related to Vaccinia:

20
Skin

MalaCards organs/tissues related to Vaccinia:

42
T Cells, Skin, Prostate, Testes, Nk Cells, Monocytes, B Cells

Publications for Vaccinia

Articles related to Vaccinia:

(show top 50) (show all 3232)
# Title Authors Year
1
Comparative purification and characterization of hepatitis B virus-like particles produced by recombinant vaccinia viruses in human hepatoma cells and human primary hepatocytes. ( 30794666 )
2019
2
Potent Anti-Hepatitis C (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-launched RNA Replicons and MVA-HCV. ( 30674625 )
2019
3
Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer. ( 30365143 )
2019
4
PD-1 blockade following isolated limb perfusion with vaccinia virus prevents local and distant relapse of soft-tissue sarcoma. ( 30885937 )
2019
5
The Vaccinia virion: Filling the gap between atomic and ultrastructure. ( 30615658 )
2019
6
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. ( 30626434 )
2019
7
Proteomics Analysis Reveals That Structural Proteins of the Virion Core and Involved in Gene Expression Are the Main Source for HLA Class II Ligands in Vaccinia Virus-Infected Cells. ( 30629447 )
2019
8
Species-specific inhibition of antiviral protein kinase R by capripoxviruses and vaccinia virus. ( 30644558 )
2019
9
Opposite effects of Vaccinia and modified Vaccinia Ankara on trained immunity. ( 30719592 )
2019
10
Differential Response Following Infection of Mouse CNS with Virulent and Attenuated Vaccinia Virus Strains. ( 30759813 )
2019
11
Prime boost immunisations with DNA, MVA and protein-based vaccines elicit robust HIV-1, Tier 2 neutralizing antibodies against the CAP256 superinfecting virus. ( 30760570 )
2019
12
Vaccinia virus BBK E3 ligase adaptor A55 targets importin-dependent NF-κB activation and inhibits CD8+ T-cell memory. ( 30814284 )
2019
13
Molecular basis of cullin-3 (Cul3) ubiquitin ligase subversion by vaccinia virus protein A55. ( 30819806 )
2019
14
NF-κB activation is a turn on for vaccinia virus phosphoprotein A49 to turn off NF-κB activation. ( 30819886 )
2019
15
Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. ( 30851967 )
2019
16
Selection of vaccinia virus-neutralizing antibody from a phage-display human-antibody library. ( 30856707 )
2019
17
The Perennial Use of the Green Fluorescent Protein Marker in a Live Vaccinia Virus Ankara Recombinant Platform Shows No Acute Adverse Effects in Mice. ( 30877662 )
2019
18
Oncolytic cancer therapy with a vaccinia virus strain. ( 30365140 )
2019
19
Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility. ( 30420785 )
2019
20
Engineering oncolytic vaccinia virus with functional peptides through mild and universal strategy. ( 30523361 )
2019
21
<i>Tachypleus tridentatus</i> Lectin Enhances Oncolytic Vaccinia Virus Replication to Suppress In Vivo Hepatocellular Carcinoma Growth. ( 29880736 )
2018
22
Ocular Vaccinia Infection in Dairy Worker, Brazil. ( 29260673 )
2018
23
First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. ( 29669026 )
2018
24
Vaccinia virus in Feces and Urine of Wild Rodents from SALo Paulo State, Brazil. ( 29360742 )
2018
25
Antigenicity of <i>Leishmania</i>-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters. ( 29740446 )
2018
26
Vaccinia virus C9 ankyrin-repeat/F-box protein is a newly identified antagonist of the type I interferon-induced antiviral state. ( 29444943 )
2018
27
Genital Autoinoculation with Vaccinia: A Look at Two Cases. ( 29415160 )
2018
28
Vaccinia-based vaccines to biothreat and emerging viruses. ( 29779454 )
2018
29
Inhibition of vaccinia virus replication by nitazoxanide. ( 29625403 )
2018
30
High Initial Sputter Rate Found for Vaccinia Virions Using Isotopic Labeling, NanoSIMS, and AFM. ( 29295620 )
2018
31
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. ( 29259007 )
2018
32
E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox. ( 29300297 )
2018
33
Vaccinia Virus Protein C6: A Multifunctional Interferon Antagonist. ( 29785476 )
2018
34
In vitro susceptibility to ST-246 and Cidofovir corroborates the phylogenetic separation of Brazilian Vaccinia virus into two clades. ( 29427676 )
2018
35
Vaccinia Virus in Blood Samples of Humans, Domestic and Wild Mammals in Brazil. ( 29346277 )
2018
36
A Novel System for Constructing a Recombinant Highly-Attenuated Vaccinia Virus Strain (LC16m8) Expressing Foreign Genes and Its Application for the Generation of LC16m8-Based Vaccines against Herpes Simplex Virus 2. ( 29709968 )
2018
37
DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination. ( 29869530 )
2018
38
Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase. ( 29599502 )
2018
39
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines. ( 29692427 )
2018
40
Septins suppress the release of vaccinia virus from infected cells. ( 29921601 )
2018
41
Lamin A/C augments Th1 differentiation and response against vaccinia virus and Leishmania major. ( 29311549 )
2018
42
The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host. ( 29678552 )
2018
43
Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-I94 with a Set of Gene Deletions on Several Viral Pathways. ( 29367944 )
2018
44
Weak vaccinia virus-induced NK cell regulation of CD4 T cells is associated with reduced NK cell differentiation and cytolytic activity. ( 29715623 )
2018
45
Mechanism of vaccinia viral protein B14-mediated inhibition of II_B kinase I^ activation. ( 29748387 )
2018
46
Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine. ( 29922280 )
2018
47
Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis. ( 29773661 )
2018
48
<i>Haliotis discus discus</i> Sialic Acid-Binding Lectin Reduces the Oncolytic Vaccinia Virus Induced Toxicity in a Glioblastoma Mouse Model. ( 29701680 )
2018
49
Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against <i>Mycobacterium tuberculosis</i>. ( 29847865 )
2018
50
Mutagenic repair of double-stranded DNA breaks in vaccinia virus genomes requires cellular DNA ligase IV activity in the cytosol. ( 29676720 )
2018

Variations for Vaccinia

Expression for Vaccinia

Search GEO for disease gene expression data for Vaccinia.

Pathways for Vaccinia

Pathways related to Vaccinia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 BTRC CUL1 CYB5R3 DUSP3 EIF2AK2 IL2
2
Show member pathways
12.83 IL2 IRF3 IRF7 NLRP1 TANK
3
Show member pathways
12.32 AZI2 IRF3 IRF7 TANK TBKBP1
4
Show member pathways
12.2 CUL1 EIF2AK2 IL2 IRF3 IRF7
5
Show member pathways
11.77 BTRC CUL1 IRF7 TANK
6 11.61 IL2 IRF3 IRF7 NLRP1 TANK TBKBP1
7
Show member pathways
10.49 EIF2AK2 IRF3 IRF7

GO Terms for Vaccinia

Cellular components related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.44 BANF1 BTRC CUL1 DUSP3 EIF2AK2 EPS15

Biological processes related to Vaccinia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.91 EIF2AK2 IL2 IRF3 IRF7 NLRP1
2 innate immune response GO:0045087 9.88 EIF2AK2 IRF3 IRF7 NLRP1 TBKBP1
3 peptidyl-serine phosphorylation GO:0018105 9.73 VRK1 VRK2 VRK3
4 response to virus GO:0009615 9.7 BANF1 EIF2AK2 IRF7
5 peptidyl-threonine phosphorylation GO:0018107 9.58 VRK1 VRK2 VRK3
6 NIK/NF-kappaB signaling GO:0038061 9.55 BTRC CUL1
7 positive regulation of kinase activity GO:0033674 9.54 IL2 ITSN1
8 positive regulation of interferon-alpha production GO:0032727 9.49 IRF3 IRF7
9 regulation of type I interferon production GO:0032479 9.46 IRF3 IRF7
10 viral process GO:0016032 9.44 AZI2 BANF1 BTRC CUL1 EIF2AK2 EPS15
11 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.43 IRF3 IRF7
12 mitotic nuclear envelope reassembly GO:0007084 9.37 BANF1 VRK1
13 MDA-5 signaling pathway GO:0039530 9.32 IRF3 IRF7
14 type I interferon biosynthetic process GO:0045351 9.26 IRF3 IRF7
15 interferon-alpha production GO:0032607 9.16 AZI2 IRF7
16 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.13 IRF3 IRF7 TANK

Molecular functions related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 AZI2 BANF1 BTRC CUL1 CYB5R3 EIF2AK2
2 kinase activator activity GO:0019209 8.96 IL2 ITSN1

Sources for Vaccinia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....